1700637101
1700637102
（3）已经治愈的感染性假肢关节关节炎。
1700637103
1700637104
（4）有高感染风险者。
1700637105
1700637106
生物制剂的疗效是肯定的，但仍然有许多问题有待长期观察。如长期使用生物制剂治疗的安全性如何？患者是否可以停药？停药后复发率如何？不同生物制剂之间如何进行转换？免疫系统是复杂的网络系统，生物制剂是否因抑制某一环节而导致其他免疫反应的异常活化，从而削弱某些保护作用，增加其他免疫病发生的可能？上述问题都有待进一步探讨。
1700637107
1700637108
【思考题】
1700637109
1700637110
1．常用生物制剂的种类及主要特性有哪些？
1700637111
1700637112
2．试述生物制剂治疗类风湿关节炎的疗效。
1700637113
1700637114
3．生物制剂常见不良反应有哪些？
1700637115
1700637116
4．使用生物制剂的注意事项有哪些？
1700637117
1700637118
参考文献
1700637119
1700637120
[1] Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med, 1999, 130(6)
:478-486.
1700637121
1700637122
[2] Smolen JS, Van Der Heijde DM, St Clair EW, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset（ASPIRE）Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum, 2006, 54(3)
:702-710.
1700637123
1700637124
[3] Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 2006, 54(1)
:26-37.
1700637125
1700637126
[4] Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 2004, 350(25)
:2572-2581.
1700637127
1700637128
[5] Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase Ⅱb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum, 2005, 52(8)
:2263-2271.
1700637129
1700637130
[6] Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 2004, 50(6)
:1761-1769
1700637131
1700637132
[7] Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet, 2002, 359(9313)
:1187-1193.
1700637133
1700637134
[8] Davis JC, van der Heijde D, Dougados M, et al. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum, 2005, 53(4)
:494-501.
1700637135
1700637136
[9] Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab（anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol, 2008, 126(3)
:282-90.
1700637137
1700637138
[10] Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome（TRIPSS). Arthritis Rheum, 2004, 50(4)
:1270-6.
1700637139
1700637140
[11] Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 2006, 295(19)
:2275-2285.
1700637141
1700637142
[12] Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol, 2006, 33(5)
:854-861.
1700637143
1700637144
[13] Orpin SD, Majmudar VB, Soon C. Adalimumab causing vasculitis. Br J Dermatol, 2006, 154(5)
:998-999.
1700637145
1700637146
（吴华香）
1700637147
1700637148
1700637149
1700637150
[
上一页 ]
[ :1.700637101e+09 ]
[
下一页 ]